RU2015146871A - Сухие порошки с тиотропием - Google Patents
Сухие порошки с тиотропием Download PDFInfo
- Publication number
- RU2015146871A RU2015146871A RU2015146871A RU2015146871A RU2015146871A RU 2015146871 A RU2015146871 A RU 2015146871A RU 2015146871 A RU2015146871 A RU 2015146871A RU 2015146871 A RU2015146871 A RU 2015146871A RU 2015146871 A RU2015146871 A RU 2015146871A
- Authority
- RU
- Russia
- Prior art keywords
- dry powder
- inhalation
- paragraphs
- particles
- dry
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Otolaryngology (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (23)
1. Пригодный для вдыхания сухой порошок, включающий пригодные для вдыхания сухие частицы, которые содержат хлорид натрия, лейцин и тиотропий бромид, причем хлорид натрия составляет от 67% до 84%, лейцин составляет от 12% до 28%, тиотропий бромид составляет от примерно 0,01% до примерно 0,5%, и необязательно один или несколько дополнительных терапевтических компонентов в количестве вплоть до примерно 20%, причем все проценты являются массовыми в расчете на сухую основу и сумма всех компонентов пригодных для вдыхания сухих частиц составляет 100%.
2. Пригодный для вдыхания сухой порошок по п. 1, в котором хлорид натрия составляет от 75% до 82% и лейцин составляет от 15% до 25%.
3. Пригодный для вдыхания сухой порошок по п. 1, причем хлорид натрия составляет от примерно 79,5% до примерно 80,5% и лейцин составляет от примерно 19,5% до примерно 20,5%.
4. Пригодный для вдыхания сухой порошок, включающий пригодные для вдыхания сухие частицы, которые состоят из хлорида натрия, лейцина и тиотропий бромида, причем соотношение хлорида натрия и лейцина составляет от 2,5:1 до 8:1 (масс/масс), тиотропий бромид составляет от примерно 0,01% до примерно 0,5% и необязательно один или несколько дополнительных терапевтических компонентов составляют до примерно 20%, причем все проценты являются массовыми в расчете на сухую основу и сумма всех компонентов пригодных для вдыхания сухих частиц составляет 100%.
5. Пригодный для вдыхания сухой порошок по любому из пп. 1-4, причем пригодные для вдыхания сухие частицы имеют среднеобъемный геометрический диаметр (VMGD) примерно 5 микрометров или меньше.
6. Пригодный для вдыхания сухой порошок по любому из пп. 1-4, причем сухой порошок имеет величину MMAD от примерно 1 микрона до примерно 5 микрон.
7. Пригодный для вдыхания сухой порошок по любому из пп. 1-4, в котором соотношение дисперсности сухих частиц 1/4 бар (1/4 бар) составляет менее примерно 1,5 по данным лазерной дифракции.
8. Пригодный для вдыхания сухой порошок по любому из пп. 1-4, причем в сухом порошке доля FPF частиц меньше 3,4 микрон составляет примерно 25% или более от общего количества порошка.
9. Пригодный для вдыхания сухой порошок по любому из пп. 1-4, причем меньшей мере 80% пригодных для вдыхания сухих частиц порошка удаляются из капсулы при распылении из пассивного сухопорошкового ингалятора с сопротивлением примерно 0,036 кв.корень(кПа)/л в минуту при следующих условиях: энергия ингаляции 2,3 Дж при скорости потока 30 л/мин, используемые капсулы размера 3 содержат общую массу порошка 10 мг, причем указанная общая масса состоит из пригодных для вдыхания сухих частиц, и среднеобъемный геометрический диаметр пригодных для вдыхания сухих частиц, распыляемых из ингалятора, по данным лазерной дифракции, составляет 5 микрон или менее.
10. Пригодный для вдыхания сухой порошок по любому из пп. 1-4 для применения в лечении респираторного заболевания у больного, причем применение включает введение в дыхательные пути пациента, страдающего респираторным заболеванием, эффективного количества сухого порошка.
11. Пригодный для вдыхания сухой порошок по любому из пп. 1-4 для применения в лечении или уменьшении частоты или тяжести острого обострения респираторного заболевания у больного, причем использование включает введение в дыхательные пути больного эффективного количества пригодного для вдыхания сухого порошка, в результате чего происходит лечение или уменьшение частоты или тяжести острого обострения респираторного заболевания.
12. Пригодный для вдыхания сухой порошок по п. 10, где респираторным заболеванием является хроническое обструктивное легочное заболевание ХОБЛ.
13. Сухопорошковый ингалятор, содержащий пригодный для вдыхания сухой порошок по любому из пп. 1-4, где сухопорошковый ингалятор представляет собой капсульный сухопорошковый ингалятор или блистерный сухопорошковый ингалятор.
14. Контейнер, содержащий пригодный для вдыхания сухой порошок по любому из пп. 1-4, где контейнер представляет собой капсулу или блистер и где контейнер содержит примерно 15 мг сухого порошка или меньше.
15. Контейнер, содержащий пригодный для вдыхания сухой порошок по любому из пп. 1-4, который содержит примерно 7,5 мг сухого порошка.
16. Контейнер, содержащий пригодный для вдыхания сухой порошок по любому из пп. 1-4, который содержит примерно 5 мг сухого порошка.
17. Контейнер по п. 14, который содержит номинальную дозу тиотропия от примерно 3 до примерно 9 микрограмм.
18. Пригодный для вдыхания сухой порошок по любому из пп. 1-4, который содержит пригодные для вдыхания сухие частицы с насыпной плотностью более 0,4 г/см3.
19. Пригодный для вдыхания сухой порошок по любому из пп. 1-4, в котором доля мелких частиц менее 5.0 микрон содержит от примерно 1 микрограмм до примерно 5 микрограмм тиотропия.
20. Пригодный для вдыхания сухой порошок по любому из пп. 1-4, в котором соотношение доли мелких частиц меньше 2,0 мкм и доли мелких частиц меньше 5.0 микрон составляет менее примерно 0,25.
21. Контейнер по п. 14, который содержит номинальную дозу тиотропия от примерно 1,5 микрограмм до примерно 12 микрограмм.
22. Пригодный для вдыхания сухой порошок по любому из пп. 1-4, в котором один или несколько дополнительных терапевтических компонентов представляют собой один или несколько кортикостероидов.
23. Пригодный для вдыхания сухой порошок по любому из пп. 1-4, причем по меньшей мере 80% пригодных для вдыхания сухих частиц порошка удаляются из капсулы при распылении из пассивного сухопорошкового ингалятора с сопротивлением примерно 0,048 кв.корень(кПа)/л в минуту при следующих условиях: энергия ингаляции 1,8 Дж при скорости потока 20 л/мин с использованием капсул размера 3, которые содержат общую массу 5 мг, причем указанная общая масса состоит из пригодных для вдыхания сухих частиц и среднеобъемный геометрический диаметр пригодных для вдыхания сухих частиц, распыленных из ингалятора, составляет 5 микрон или менее, по данным лазерной дифракции.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361807063P | 2013-04-01 | 2013-04-01 | |
US61/807,063 | 2013-04-01 | ||
US201361874146P | 2013-09-05 | 2013-09-05 | |
US61/874,146 | 2013-09-05 | ||
US201461925400P | 2014-01-09 | 2014-01-09 | |
US61/925,400 | 2014-01-09 | ||
PCT/US2014/025660 WO2014165303A1 (en) | 2013-04-01 | 2014-03-13 | Tiotropium dry powders |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2015146871A true RU2015146871A (ru) | 2017-05-10 |
RU2015146871A3 RU2015146871A3 (ru) | 2018-03-05 |
Family
ID=50693973
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2015146871A RU2015146871A (ru) | 2013-04-01 | 2014-03-13 | Сухие порошки с тиотропием |
Country Status (11)
Country | Link |
---|---|
US (2) | US9737518B2 (ru) |
EP (1) | EP2981247B1 (ru) |
JP (1) | JP6473738B2 (ru) |
KR (1) | KR20150135328A (ru) |
CN (1) | CN105324106A (ru) |
AU (1) | AU2014248455B2 (ru) |
CA (1) | CA2907566C (ru) |
HK (1) | HK1221175A1 (ru) |
MX (1) | MX2015013845A (ru) |
RU (1) | RU2015146871A (ru) |
WO (1) | WO2014165303A1 (ru) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NO2699580T3 (ru) | 2014-01-24 | 2018-02-24 | ||
US20170304197A1 (en) * | 2014-10-08 | 2017-10-26 | Pulmatrix Operating Company, Inc. | Formulations containing tiotropium, amino acid and acid and methods thereof |
JP2019500916A (ja) * | 2015-10-23 | 2019-01-17 | アーヴェン イラチュ サナイ ヴェ ティヂャレット エー. エス.Arven Ilac Sanayi Ve Ticaret A.S. | 臭化チオトロピウムの吸入製剤のためのブリスター |
WO2018022978A1 (en) * | 2016-07-29 | 2018-02-01 | Insmed Incorporated | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating bronchiectasis |
CA3039485A1 (en) * | 2016-10-14 | 2018-04-19 | Pulmatrix Operating Company, Inc. | Antifungal dry powders |
ES2907692T3 (es) * | 2017-12-29 | 2022-04-26 | Celon Pharma Sa | Composición de ketamina de polvo seco para su administración por vía pulmonar en la depresión resistente al tratamiento |
EP3760189A4 (en) * | 2018-02-26 | 2022-01-05 | Shin Nippon Biomedical Laboratories, Ltd. | PULVERULENT PREPARATION, CARTRIDGE AND DEVICE |
CN110161142A (zh) * | 2019-06-11 | 2019-08-23 | 珠海瑞思普利生物制药有限公司 | 一种表征干粉吸入制剂在呼吸系统空气动力学的仿真装置 |
BE1027612B1 (fr) * | 2019-09-10 | 2021-05-03 | Aquilon Pharmaceuticals | Microparticules en forme de balle de golf pour une utilisation dans le traitement et la prevention de maladies pulmonaires |
CN117222401A (zh) * | 2021-03-03 | 2023-12-12 | 普马特里克斯营业公司 | 二氢麦角胺干粉制剂及其使用方法 |
EP4108230A1 (en) * | 2021-06-24 | 2022-12-28 | Laboratoires SMB | New dry powder composition of tiotropium for inhalation |
CN114272228B (zh) * | 2022-01-04 | 2023-08-22 | 丽珠医药集团股份有限公司 | 噻托溴铵吸入微球及其制备方法和吸入式制剂 |
CN117233286A (zh) * | 2023-09-19 | 2023-12-15 | 南京力成药业有限公司 | 一种噻托溴铵的定量检测方法 |
Family Cites Families (197)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1575050A1 (de) | 1966-01-12 | 1972-04-13 | Misto Gen Equipment Co | Ultraschall-Nebelerzeugungsgeraet |
US4069819A (en) | 1973-04-13 | 1978-01-24 | Societa Farmaceutici S.P.A. | Inhalation device |
US4085893A (en) | 1974-03-20 | 1978-04-25 | Durley Iii Benton A | Ultrasonic humidifiers, atomizers and the like |
US4193009A (en) | 1976-01-26 | 1980-03-11 | Durley Benton A Iii | Ultrasonic piezoelectric transducer using a rubber mounting |
JPS5550437U (ru) | 1978-09-28 | 1980-04-02 | ||
US4233405A (en) | 1979-10-10 | 1980-11-11 | Rohm And Haas Company | Process for spray drying enzymes |
DE3229179C2 (de) | 1982-08-05 | 1986-04-17 | A. Nattermann & Cie GmbH, 5000 Köln | Lungensurfactant |
KR900001873B1 (ko) | 1984-06-14 | 1990-03-26 | 산요덴끼 가부시끼가이샤 | 초음파 가습장치 |
US4637815A (en) | 1985-08-06 | 1987-01-20 | Lemole Gerald M | Irrigational hemostatic solution |
FI82808C (fi) | 1987-12-31 | 1991-04-25 | Etelae Haemeen Keuhkovammayhdi | Ultraljudfinfoerdelningsanordning. |
US4899914A (en) | 1988-11-04 | 1990-02-13 | Ciba-Geigy Corporation | Method for producing a sterile preservative-free aerosol saline solution |
US4921639A (en) | 1988-11-09 | 1990-05-01 | Bernard Chiu | Ultrasonic humidifier |
US4881541A (en) | 1988-12-21 | 1989-11-21 | The Regents Of The University Of California | Vaporizer for an anesthetic having a vapor pressure about one atmosphere |
IT1228459B (it) | 1989-02-23 | 1991-06-19 | Phidea S R L | Inalatore con svuotamento regolare e completo della capsula. |
DE3931041C2 (de) | 1989-09-16 | 2000-04-06 | Boehringer Ingelheim Kg | Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel |
US5610163A (en) | 1989-09-16 | 1997-03-11 | Boehringer Ingelheim Gmbh | Esters of thienyl carboxylic acids and amino alcohols and their quaternization products |
US5230884A (en) | 1990-09-11 | 1993-07-27 | University Of Wales College Of Cardiff | Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations |
US5175152A (en) | 1990-09-28 | 1992-12-29 | Singh Nikhilesh N | Composition containing ephedrine base and alkyl salicylate for the delivery of ephedrine base in vapor form |
US5211944A (en) | 1990-10-12 | 1993-05-18 | Shaman Pharmaceuticals, Inc. | Proanthocyanidin polymers having antiviral activity and methods of obtaining same |
US5571535A (en) | 1990-11-30 | 1996-11-05 | Flowers; Marianne | Treatment of topical infections |
ES2284226T3 (es) | 1991-07-02 | 2007-11-01 | Nektar Therapeutics | Dispositivo para proporcionar medicamentos en aerosol. |
JPH05123398A (ja) | 1991-11-06 | 1993-05-21 | Tsunemasa Kamiyama | 咽喉保護吸入剤並びに吸入器具 |
GB2265845B (en) | 1991-11-12 | 1996-05-01 | Medix Ltd | A nebuliser and nebuliser control system |
US5466680A (en) | 1992-03-26 | 1995-11-14 | Cytologics, Inc. | Method and compositions for enhancing white blood cell functioning on a mucosal or cutaneous surface |
JP3961029B2 (ja) | 1992-06-24 | 2007-08-15 | 博 木戸 | インフルエンザウィルス感染防止剤 |
US5785049A (en) | 1994-09-21 | 1998-07-28 | Inhale Therapeutic Systems | Method and apparatus for dispersion of dry powder medicaments |
US6582728B1 (en) | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
US5898037A (en) | 1992-11-13 | 1999-04-27 | Marx; Alvin J. | Formulations of magnesium compounds for local application and methods of treatment using the same |
US5709202A (en) | 1993-05-21 | 1998-01-20 | Aradigm Corporation | Intrapulmonary delivery of aerosolized formulations |
NZ328476A (en) | 1993-06-24 | 1999-05-28 | Astra Ab | Use of a two component insulin preparation in an inhalation device |
US5514665A (en) | 1993-12-30 | 1996-05-07 | University Of British Columbia | Method of preventing or reducing the risk of infection by bacterial pathogens utilizing simple and conjugated dextrans |
AUPM411494A0 (en) | 1994-02-25 | 1994-03-24 | Central Sydney Area Health Service | Method and device for the provocation of upper or lower airway narrowing and/or the induction of sputum |
US5633003A (en) | 1994-03-31 | 1997-05-27 | Cantor; Jerome O. | Use of intratracheally administered hyaluronic acid to ameliorate emphysema |
JP3414539B2 (ja) | 1994-05-11 | 2003-06-09 | 有限会社ドット | 経鼻吸収用組成物 |
US6586006B2 (en) | 1994-08-04 | 2003-07-01 | Elan Drug Delivery Limited | Solid delivery systems for controlled release of molecules incorporated therein and methods of making same |
US6290991B1 (en) | 1994-12-02 | 2001-09-18 | Quandrant Holdings Cambridge Limited | Solid dose delivery vehicle and methods of making same |
ATE218132T1 (de) | 1994-10-14 | 2002-06-15 | Yamanouchi Pharma Co Ltd | Azol-derivate |
US5863563A (en) | 1994-10-20 | 1999-01-26 | Alphagene Inc. | Treatment of pulmonary conditions associated with insufficient secretion of surfactant |
US5747002A (en) | 1995-04-05 | 1998-05-05 | Genentech, Inc. | Preparation of sodium chloride aerosol formulations |
US5612053A (en) | 1995-04-07 | 1997-03-18 | Edward Mendell Co., Inc. | Controlled release insufflation carrier for medicaments |
US6258341B1 (en) | 1995-04-14 | 2001-07-10 | Inhale Therapeutic Systems, Inc. | Stable glassy state powder formulations |
US6165463A (en) | 1997-10-16 | 2000-12-26 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
US5654007A (en) | 1995-06-07 | 1997-08-05 | Inhale Therapeutic Systems | Methods and system for processing dispersible fine powders |
GB9515182D0 (en) | 1995-07-24 | 1995-09-20 | Co Ordinated Drug Dev | Improvements in and relating to powders for use in dry powder inhalers |
US5628984A (en) | 1995-07-31 | 1997-05-13 | University Of North Carolina At Chapel Hill | Method of detecting lung disease |
US20050054682A1 (en) | 1996-01-04 | 2005-03-10 | Phillips Jeffrey O. | Pharmaceutical compositions comprising substituted benzimidazoles and methods of using same |
GB9606677D0 (en) | 1996-03-29 | 1996-06-05 | Glaxo Wellcome Inc | Process and device |
US6083922A (en) | 1996-04-02 | 2000-07-04 | Pathogenesis, Corp. | Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis |
US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
US6254854B1 (en) | 1996-05-24 | 2001-07-03 | The Penn Research Foundation | Porous particles for deep lung delivery |
US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
USRE37053E1 (en) | 1996-05-24 | 2001-02-13 | Massachusetts Institute Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
DE19653969A1 (de) | 1996-12-20 | 1998-06-25 | Boehringer Ingelheim Kg | Neue wässrige Arzneimittelzubereitung zur Erzeugung treibgasfreier Aerosole |
US20030203036A1 (en) | 2000-03-17 | 2003-10-30 | Gordon Marc S. | Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients |
GB9707934D0 (en) | 1997-04-18 | 1997-06-04 | Danbiosyst Uk | Improved delivery of drugs to mucosal surfaces |
US5881720A (en) | 1997-04-29 | 1999-03-16 | The Procter & Gamble Company | Method of delivering halotherapy |
US6339075B1 (en) | 1997-06-30 | 2002-01-15 | The University Of British Columbia | Use of dextran and other polysaccharides to improve mucus clearance |
US6565885B1 (en) | 1997-09-29 | 2003-05-20 | Inhale Therapeutic Systems, Inc. | Methods of spray drying pharmaceutical compositions |
CA2327670A1 (en) | 1998-04-08 | 1999-10-14 | Darrel Lavern Allen | Pulmonary and nasal delivery of raloxifene |
US5883084A (en) | 1998-06-08 | 1999-03-16 | Clarion Pharmaceuticals Inc. | Treatment of respiratory diseases utilizing α-tocopheryl-phosphocholine |
SE9802073D0 (sv) | 1998-06-11 | 1998-06-11 | Astra Ab | New use |
FR2780285B1 (fr) | 1998-06-29 | 2001-10-05 | Goemar Lab Sa | Utilisation de solutions salines isoosmotiques, leur procede de preparation et medicaments anti-inflammatoires a base de ces solutions |
US6333051B1 (en) | 1998-09-03 | 2001-12-25 | Supratek Pharma, Inc. | Nanogel networks and biological agent compositions thereof |
US6428814B1 (en) | 1999-10-08 | 2002-08-06 | Elan Pharma International Ltd. | Bioadhesive nanoparticulate compositions having cationic surface stabilizers |
GB9827145D0 (en) | 1998-12-09 | 1999-02-03 | Co Ordinated Drug Dev | Improvements in or relating to powders |
JP3312216B2 (ja) | 1998-12-18 | 2002-08-05 | オムロン株式会社 | 噴霧装置 |
US6926911B1 (en) | 1998-12-22 | 2005-08-09 | The University Of North Carolina At Chapel Hill | Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs |
ES2228467T3 (es) | 1999-02-03 | 2005-04-16 | Biosante Pharmaceuticals, Inc. | Particulas terapeuticas de fosfato calcico y metodos de fabricacion y su uso. |
EP1173245B1 (en) | 1999-05-03 | 2004-09-01 | Battelle Memorial Institute | Compositions for aerosolization and inhalation |
US6858199B1 (en) | 2000-06-09 | 2005-02-22 | Advanced Inhalation Research, Inc. | High efficient delivery of a large therapeutic mass aerosol |
JP2003507411A (ja) | 1999-08-25 | 2003-02-25 | アドバンスト インハレーション リサーチ,インコーポレイテッド | 噴霧乾燥大多孔性粒子製剤 |
US7678364B2 (en) | 1999-08-25 | 2010-03-16 | Alkermes, Inc. | Particles for inhalation having sustained release properties |
US6749835B1 (en) | 1999-08-25 | 2004-06-15 | Advanced Inhalation Research, Inc. | Formulation for spray-drying large porous particles |
MXPA02004193A (es) | 1999-10-29 | 2002-12-13 | Inhale Therapeutic Syst | Composiciones de polvo seco que tienen caracteristicas de dispersion mejoradas. |
US6962151B1 (en) | 1999-11-05 | 2005-11-08 | Pari GmbH Spezialisten für effektive Inhalation | Inhalation nebulizer |
AU772096B2 (en) | 2000-03-14 | 2004-04-08 | Sumika Enviro-Science Co., Ltd. | Method for denaturing allergens |
SK284948B6 (sk) | 2000-04-06 | 2006-03-02 | Zentiva, A. S. | Liečivý prípravok s obsahom vápnika alebo zmesi vápnika a vitamínu D, alebo zmesi vápnika a horčíka v novej liekovej forme |
GB0008660D0 (en) | 2000-04-07 | 2000-05-31 | Arakis Ltd | The treatment of respiratory diseases |
US6637432B2 (en) | 2000-05-09 | 2003-10-28 | Iep Pharmaceutical Devices Inc. | Inhalation actuated device |
US7871598B1 (en) | 2000-05-10 | 2011-01-18 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
TWI290473B (en) | 2000-05-10 | 2007-12-01 | Alliance Pharma | Phospholipid-based powders for drug delivery |
WO2002000197A1 (en) | 2000-06-27 | 2002-01-03 | Vectura Limited | Method of making particles for use in a pharmaceutical composition |
US7575761B2 (en) | 2000-06-30 | 2009-08-18 | Novartis Pharma Ag | Spray drying process control of drying kinetics |
US6669959B1 (en) | 2000-07-18 | 2003-12-30 | Aeropharm Technology Incorporated | Modulated release particles for lung delivery |
AU2001278131A1 (en) | 2000-08-01 | 2002-02-13 | Shofner Engineering Associates, Inc. | Generation, delivery, measurement and control of aerosol boli for diagnostics and treatments of the respiratory/pulmonary tract of a patient |
US6613308B2 (en) | 2000-09-19 | 2003-09-02 | Advanced Inhalation Research, Inc. | Pulmonary delivery in treating disorders of the central nervous system |
WO2002024116A1 (en) | 2000-09-20 | 2002-03-28 | Shahinian, Lee, Jr. | Self-preserved nasal, inhalable, and topical ophthalmic preparations and medications |
US20040081627A1 (en) | 2000-10-09 | 2004-04-29 | Jinks Phillip A | Medicinal aerosol formulations |
US6908928B2 (en) | 2000-10-12 | 2005-06-21 | Bi Pharma Kg. | Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions |
PT1920763E (pt) | 2000-11-30 | 2014-06-25 | Vectura Ltd | Composições farmacêuticas para inalação |
CA2432319A1 (en) | 2000-12-21 | 2002-07-18 | Nektar Therapeutics | Pulmonary delivery of polyene antifungal agents |
DE10064816A1 (de) | 2000-12-22 | 2002-06-27 | Boehringer Ingelheim Pharma | Verfahren zur Herstellung eines Anticholinergikums |
ES2406405T3 (es) | 2000-12-27 | 2013-06-06 | Gilead Sciences, Inc. | Aztreonam inhalable sin arginina para tratamiento y prevención de infecciones bacterianas pulmonares |
US20020141946A1 (en) | 2000-12-29 | 2002-10-03 | Advanced Inhalation Research, Inc. | Particles for inhalation having rapid release properties |
ES2291452T3 (es) | 2001-02-06 | 2008-03-01 | Innovata Biomed Limited | Formulacion bimodal de polvo seco para inhalacion. |
US6546927B2 (en) | 2001-03-13 | 2003-04-15 | Aerogen, Inc. | Methods and apparatus for controlling piezoelectric vibration |
US6550472B2 (en) | 2001-03-16 | 2003-04-22 | Aerogen, Inc. | Devices and methods for nebulizing fluids using flow directors |
US20030022829A1 (en) | 2001-03-30 | 2003-01-30 | Wendy Maury | Novel antiviral activities primate theta defensins and mammalian cathelicidins |
US6766799B2 (en) | 2001-04-16 | 2004-07-27 | Advanced Inhalation Research, Inc. | Inhalation device |
US6667344B2 (en) | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
US6511050B2 (en) | 2001-05-02 | 2003-01-28 | Dynamo Aviation, Inc. | Humidifier |
US6608055B2 (en) | 2001-06-22 | 2003-08-19 | Boehringer Ingelheim Pharma Kg | Crystalline anticholinergic, processes for preparing it and its use for preparing a pharmaceutical composition |
US20030138403A1 (en) | 2001-06-29 | 2003-07-24 | Maxygen Aps | Interferon formulations |
JP2003074919A (ja) | 2001-08-31 | 2003-03-12 | Sunbow Precision Co Ltd | 複合式加湿器 |
US20050123509A1 (en) | 2001-10-19 | 2005-06-09 | Lehrman S. R. | Modulating charge density to produce improvements in the characteristics of spray-dried proteins |
US20030203930A1 (en) | 2001-10-26 | 2003-10-30 | Imtiaz Chaudry | Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease |
AU2002352836B2 (en) | 2001-11-20 | 2005-09-29 | Alkermes, Inc. | Improved particulate compositions for pulmonary delivery |
IL161446A0 (en) | 2001-11-26 | 2004-09-27 | Daiichi Suntory Pharma Co Ltd | Medicinal compositions for nasal absorption |
US6851626B2 (en) | 2002-01-07 | 2005-02-08 | Aerogen, Inc. | Methods and devices for nebulizing fluids |
GB2384198B (en) | 2002-01-18 | 2005-03-02 | Profile Drug Delivery Ltd | Nebulizer metering |
GB0217199D0 (en) | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicament dispenser |
US20030232019A1 (en) | 2002-02-22 | 2003-12-18 | Advanced Inhalation Research, Inc. | Inhalable formulations for sustained release |
PT2630954T (pt) | 2002-03-20 | 2017-01-05 | Civitas Therapeutics Inc | Administração pulmonar de levodopa |
US7008644B2 (en) | 2002-03-20 | 2006-03-07 | Advanced Inhalation Research, Inc. | Method and apparatus for producing dry particles |
GB0207906D0 (en) | 2002-04-05 | 2002-05-15 | 3M Innovative Properties Co | Formoterol and mometasone aerosol formulations |
GB0209782D0 (en) | 2002-04-29 | 2002-06-05 | Glaxo Group Ltd | Medicament dispenser |
US20050220720A1 (en) | 2002-05-02 | 2005-10-06 | David Edwards | Formulations limiting spread of pulmonary infections |
US8003080B2 (en) | 2002-05-13 | 2011-08-23 | Alexza Pharmaceuticals, Inc. | Delivery of drug amines through an inhalation route |
AU2003241477A1 (en) | 2002-06-10 | 2003-12-22 | Elan Pharma International, Ltd. | Nanoparticulate polycosanol formulations and novel polycosanol combinations |
PT1531794T (pt) | 2002-06-28 | 2017-09-14 | Civitas Therapeutics Inc | Epinefrina inalável |
GB0217198D0 (en) | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicament dispenser |
US20050271660A1 (en) | 2002-09-06 | 2005-12-08 | Alexion Pharmaceuticals, Inc. | Nebulization of monoclonal antibodies for treating pulmonary diseases |
US7112572B2 (en) | 2002-09-09 | 2006-09-26 | Trigen Limited | Multivalent metal salts of boronic acids |
JP2006503865A (ja) | 2002-09-30 | 2006-02-02 | アキュスフィア, インコーポレイテッド | 吸入のための徐放性の多孔性微粒子 |
CN101804200A (zh) | 2002-11-22 | 2010-08-18 | 余芒 | 广谱抗病毒的治疗和预防 |
US7534781B2 (en) | 2003-03-21 | 2009-05-19 | Dsm Ip Assets B.V. | Crystalline amoxicillin trihydrate powder |
CN1194062C (zh) | 2003-04-04 | 2005-03-23 | 王泽斌 | 一种融雪融冰组合物及其制备方法和应用 |
NZ543201A (en) | 2003-05-01 | 2007-05-31 | Innogene Kalbiotech Pte Ltd | Lactate containing pharmaceutical composition and uses thereof |
ATE501766T1 (de) | 2003-05-20 | 2011-04-15 | James F Collins | Ophthalmisches arzneimittelabgabesystem |
US7195179B2 (en) | 2003-06-01 | 2007-03-27 | Piezo Technologies | Piezoelectric mist generation device |
JP2009514779A (ja) | 2003-07-11 | 2009-04-09 | グラクソ グループ リミテッド | 医薬製剤 |
GB0324897D0 (en) | 2003-10-24 | 2003-11-26 | Glaxo Group Ltd | Composition |
GB0324918D0 (en) | 2003-10-24 | 2003-11-26 | Glaxo Group Ltd | Composition |
US7968717B2 (en) | 2003-11-03 | 2011-06-28 | Boehringer Ingelhein International Gmbh | Crystalline anhydrate with anticholinergic efficacy |
SE0303270L (sv) | 2003-12-03 | 2005-06-04 | Microdrug Ag | Metod för administration av tiotropium |
KR20050056622A (ko) | 2003-12-10 | 2005-06-16 | 주식회사 대우일렉트로닉스 | 플레쉬롬 다운로드 장치 |
WO2005067898A2 (en) | 2004-01-07 | 2005-07-28 | Nektar Therapeutics | Improved sustained release compositions for pulmonary administration of insulin |
US20050207983A1 (en) | 2004-03-05 | 2005-09-22 | Pulmatrix, Inc. | Formulations decreasing particle exhalation |
SE528121C2 (sv) | 2004-03-29 | 2006-09-05 | Mederio Ag | Preparering av torrpulver för på förhand uppmätt DPI |
EP1734962A4 (en) | 2004-03-30 | 2010-07-14 | Painceptor Pharma Corp | COMPOSITIONS AND METHOD FOR MODULATING CONTROLLED ION CHANNELS |
CA2602596A1 (en) | 2004-03-30 | 2005-10-13 | Malcolm King | Compositions and methods for improved mucus function |
US20050281740A1 (en) | 2004-06-16 | 2005-12-22 | Glen Gong | Imaging damaged lung tissue |
GB0415789D0 (en) * | 2004-07-15 | 2004-08-18 | Astrazeneca Ab | Novel combination |
JP2008507585A (ja) | 2004-07-26 | 2008-03-13 | コセリックス インク | 微粒子製剤を用いて吸入したイロプロストによる肺高血圧症の治療 |
DE102004041253A1 (de) | 2004-08-26 | 2006-03-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neues Verfahren zur Herstellung von Tiotropiumsalzen |
JP2008512475A (ja) | 2004-09-07 | 2008-04-24 | スミスクライン・ビーチャム・コーポレイション | アゴニストによるtrpv4チャネル受容体の活性化方法 |
US20060073173A1 (en) | 2004-10-04 | 2006-04-06 | Maria Banach | Large-scale manufacturing process for the production of pharmaceutical compositions |
GB0425758D0 (en) | 2004-11-23 | 2004-12-22 | Vectura Ltd | Preparation of pharmaceutical compositions |
US8627821B2 (en) | 2005-01-10 | 2014-01-14 | Pulmatrix, Inc. | Method and device for decreasing contamination |
WO2006084131A2 (en) | 2005-02-01 | 2006-08-10 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Furin inhibitors and alpha-defensins for the treatment or prevention of papillomavirus infection |
EP2463551B1 (en) | 2005-02-10 | 2015-04-08 | BorgWarner Inc. | Dual clutch transmission |
WO2006102438A2 (en) | 2005-03-23 | 2006-09-28 | Ihc Intellectual Asset Management, Llc | Methods and compositions for irrigation of mucosal tissues |
US20060229366A1 (en) | 2005-04-07 | 2006-10-12 | Lifschitz Carlos H | Method for preventing or treating respiratory infections in infants |
AU2006243238B2 (en) | 2005-05-02 | 2012-05-24 | Boehringer Ingelheim International Gmbh | Novel crystalline forms of tiotropium bromide |
US7838532B2 (en) | 2005-05-18 | 2010-11-23 | Mpex Pharmaceuticals, Inc. | Aerosolized fluoroquinolones and uses thereof |
EA016072B1 (ru) | 2005-05-18 | 2012-01-30 | Палметрикс Инк. | Применение состава соли кальция для изменения биофизических свойств слизистой оболочки |
GB0520794D0 (en) | 2005-10-12 | 2005-11-23 | Innovata Biomed Ltd | Inhaler |
EP1952160B1 (en) | 2005-10-31 | 2011-04-06 | Janssen Pharmaceutica NV | Methods for identifying modulators of trpv2 |
GB0523576D0 (en) | 2005-11-18 | 2005-12-28 | Theradeas Ltd | Drug composition and its use in therapy |
PL2123650T3 (pl) | 2005-12-19 | 2012-09-28 | Sicor Inc | Nowa postać bromku tiotropium i sposób jej wytwarzania |
CA2640165A1 (en) | 2006-01-27 | 2007-08-02 | The Provost, Fellows And Scholars Of The College Of The Holy And Undivid Ed Trinity Of Queen Elizabeth Near Dublin | A method of producing porous microparticles |
US20070202051A1 (en) | 2006-02-10 | 2007-08-30 | Pari Gmbh | Aerosols for sinunasal drug delivery |
US20080051582A1 (en) | 2006-07-10 | 2008-02-28 | Sicor Inc. | Process for the preparation of tiotropium bromide |
EP2054339A4 (en) | 2006-08-11 | 2011-08-03 | Panacea Biotec Ltd | PARTICULARS FOR ACTIVE INHIBITION, MANUFACTURING METHOD AND COMPOSITIONS THEREOF |
WO2008025560A1 (en) | 2006-09-01 | 2008-03-06 | Pari Pharma Gmbh | Methods for taste masking of nebulised compositions for nasal and pulmonary inhalation therapy |
US20080063722A1 (en) | 2006-09-08 | 2008-03-13 | Advanced Inhalation Research, Inc. | Composition of a Spray-Dried Powder for Pulmonary Delivery of a Long Acting Neuraminidase Inhibitor (LANI) |
EP2101748B9 (en) | 2006-11-29 | 2015-02-25 | Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. | Use of incensole and derivatives thereof for neuroprotection and for the treatment of depression and anxiety |
WO2008070538A2 (en) | 2006-12-01 | 2008-06-12 | Anterios, Inc. | Micellar nanoparticles comprising botulinum toxin |
GB0625322D0 (en) | 2006-12-19 | 2007-01-24 | Pharmakodex Ltd | Pharmaceutical compositions |
GB0716026D0 (en) | 2007-08-16 | 2007-09-26 | Norton Healthcare Ltd | An inhalable medicament |
WO2009037503A2 (en) | 2007-09-18 | 2009-03-26 | Astrazeneca Ab | New combination - 012 for the treatment of respiratory diseases |
GB0719518D0 (en) | 2007-10-05 | 2007-11-14 | Therapeutics Ltd E | Therapy |
EP2050437A1 (en) | 2007-10-15 | 2009-04-22 | Laboratoires SMB | Improved pharmaceutical dry powder compositions for inhalation. |
EP2080508A1 (en) | 2008-01-15 | 2009-07-22 | CHIESI FARMACEUTICI S.p.A. | Dry powder formulation comprising an anticholinergic drug |
EP2098219A1 (en) | 2008-03-05 | 2009-09-09 | PARI Pharma GmbH | Macrolide compositions having improved taste and stability |
US8119647B2 (en) | 2008-04-23 | 2012-02-21 | Glenmark Pharmaceuticals S.A. | Fused pyrimidineone compounds as TRPV3 modulators |
MX2010012452A (es) | 2008-05-15 | 2011-03-15 | Novartis Ag Star | Suministro pulmonar de una fluoro-quinolona. |
EP2172190A1 (en) | 2008-10-02 | 2010-04-07 | Laboratorios Liconsa, S.A. | Inhalable particles comprising tiotropium |
GB0818476D0 (en) | 2008-10-09 | 2008-11-12 | Vectura Delivery Device Ltd | Inhaler |
JP2012509922A (ja) | 2008-11-27 | 2012-04-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規粉末化結晶質吸入薬 |
AU2010229721A1 (en) | 2009-03-26 | 2011-10-06 | Pulmatrix, Inc. | Methods for treating and preventing pneumonia and ventilator-associated tracheobronchitis |
KR20120002981A (ko) | 2009-03-26 | 2012-01-09 | 풀매트릭스 인코퍼레이티드 | 호흡기 감염 치료를 위한 약제 제형 및 방법 |
WO2010111680A2 (en) | 2009-03-26 | 2010-09-30 | Pulmatrix, Inc. | Dry powder formulations and methods for treating pulmonary diseases |
EP2410984A2 (en) | 2009-03-26 | 2012-02-01 | Pulmatrix, Inc. | Anti-influenza formulations and methods |
WO2010111650A2 (en) | 2009-03-26 | 2010-09-30 | Pulmatrix, Inc. | Calcium citrate and calcium lactate formulations for alteration of biophysical properties of mucosal lining |
WO2010110760A1 (en) | 2009-03-27 | 2010-09-30 | Mahmut Bilgic | Compositions comprising water with deuterium for the prevention or treatment of allergic diseases and a process for the preparation thereof |
WO2010124198A2 (en) | 2009-04-24 | 2010-10-28 | Schering Corporation | Agglomerate formulations useful in dry powder inhalers |
PL3111926T3 (pl) | 2009-05-29 | 2020-06-29 | Pearl Therapeutics, Inc. | Kompozycje, sposoby i układy do dostarczania dwóch lub większej liczby środków czynnych do układu oddechowego |
US20120172429A1 (en) | 2009-07-10 | 2012-07-05 | Woolf Clifford J | Permanently charged sodium and calcium channel blockers as anti- inflammatory agents |
TR200907236A2 (tr) | 2009-09-23 | 2011-04-21 | Bi̇lgi̇ç Mahmut | Tiotropyum kuru toz formülasyonunun blister ambalajda taşınması. |
GB0918450D0 (en) | 2009-10-21 | 2009-12-09 | Innovata Ltd | Composition |
WO2012030664A1 (en) | 2010-08-30 | 2012-03-08 | Pulmatrix, Inc. | Dry powder formulations and methods for treating pulmonary diseases |
WO2012030645A1 (en) | 2010-08-30 | 2012-03-08 | Pulmatrix, Inc. | Respirably dry powder comprising calcium lactate, sodium chloride and leucine |
IL286573B (en) * | 2010-09-29 | 2022-08-01 | Pulmatrix Operating Co Inc | Monovalent metallic cation dry powders for inhalation |
EP2627317A4 (en) | 2010-10-15 | 2014-08-20 | Glaxo Group Ltd | MEDICINAL FORMULATIONS FROM AGGREGATED NANOPARTICLES AND THEIR PREPARATION AND USE |
PT106094A (pt) | 2012-01-13 | 2013-07-15 | Hovione Farmaciencia S A | Administração por inalação de formulações com dose elevada |
-
2014
- 2014-03-13 CN CN201480019667.4A patent/CN105324106A/zh active Pending
- 2014-03-13 EP EP14723543.6A patent/EP2981247B1/en active Active
- 2014-03-13 JP JP2016505482A patent/JP6473738B2/ja active Active
- 2014-03-13 RU RU2015146871A patent/RU2015146871A/ru not_active Application Discontinuation
- 2014-03-13 AU AU2014248455A patent/AU2014248455B2/en active Active
- 2014-03-13 KR KR1020157027064A patent/KR20150135328A/ko not_active Application Discontinuation
- 2014-03-13 MX MX2015013845A patent/MX2015013845A/es unknown
- 2014-03-13 WO PCT/US2014/025660 patent/WO2014165303A1/en active Application Filing
- 2014-03-13 CA CA2907566A patent/CA2907566C/en active Active
-
2015
- 2015-09-30 US US14/870,736 patent/US9737518B2/en active Active
-
2016
- 2016-08-09 HK HK16109456.0A patent/HK1221175A1/zh unknown
-
2017
- 2017-07-14 US US15/650,437 patent/US20170312258A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP2981247B1 (en) | 2023-06-07 |
HK1221175A1 (zh) | 2017-05-26 |
JP2016515576A (ja) | 2016-05-30 |
BR112015025160A2 (pt) | 2017-07-18 |
CA2907566C (en) | 2023-08-22 |
JP6473738B2 (ja) | 2019-02-20 |
US20160120855A1 (en) | 2016-05-05 |
RU2015146871A3 (ru) | 2018-03-05 |
KR20150135328A (ko) | 2015-12-02 |
CN105324106A (zh) | 2016-02-10 |
US20170312258A1 (en) | 2017-11-02 |
AU2014248455B2 (en) | 2018-12-06 |
EP2981247A1 (en) | 2016-02-10 |
CA2907566A1 (en) | 2014-10-09 |
AU2014248455A1 (en) | 2015-10-15 |
US9737518B2 (en) | 2017-08-22 |
WO2014165303A1 (en) | 2014-10-09 |
MX2015013845A (es) | 2016-05-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2015146871A (ru) | Сухие порошки с тиотропием | |
JP2013540123A5 (ru) | ||
RU2013118453A (ru) | Катионы одновалентных металлов сухих порошков для ингаляций | |
JP2016512494A5 (ru) | ||
JP2016515576A5 (ru) | ||
Newman et al. | Therapeutic aerosols 1--physical and practical considerations. | |
JP2019534270A5 (ru) | ||
JP6669808B2 (ja) | 超低密度肺粉剤 | |
TWI653065B (zh) | 尼古丁粉末吸入器、及將尼古丁吸入至一用戶之肺中的方法 | |
JP2013224331A5 (ru) | ||
JP2011520911A5 (ru) | ||
JP2016065107A5 (ru) | ||
RU2014150422A (ru) | Новая дозировка и препаративная форма | |
JP2013536845A5 (ru) | ||
JP2023086774A (ja) | 乾燥粉末配合および使用方法 | |
JP2017502064A5 (ru) | ||
JP2017513649A5 (ru) | ||
RU2019100425A (ru) | Новая доза и препаративная форма | |
Pomázi et al. | Effect of polymers for aerolization properties of mannitol-based microcomposites containing meloxicam | |
JP2020527377A5 (ru) | ||
IL167009A (en) | Dry powder formoterol or its derivatives for inhalation | |
JP2015519356A5 (ru) | ||
RU2018112077A (ru) | Направленная доставка высушенных распылением композиций в легкие | |
SE527190C2 (sv) | Inhalatoranordning samt kombinerade doser av en beta2-agonist, ett antikolinergiskt medel och ett antiinflammatorisk steroid | |
EA201401354A1 (ru) | Новая дозированная форма и препарат, содержащий абедитерол |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20190219 |